Lakeside Partners with Huiyu Pharmaceutical to Revolutionize Oncology Drug Distribution

Rhea-AI Summary

Lakeside Holding (Nasdaq: LSH) has announced that Hupan Pharmaceutical has entered into a strategic distribution agreement with Huiyu Pharmaceutical (Shanghai: 688553.SS). Under the agreement, Hupan Pharmaceutical will distribute Huiyu's oncology and immunotherapy drugs to healthcare institutions in domestic and global markets.

Huiyu Pharmaceutical's flagship product, Pemetrexed Disodium for Injection, has received regulatory approvals in major markets including China, the UK, Germany, and Finland. The product is recognized for treating non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

The partnership aims to expand the reach of Huiyu's innovative oncology solutions and deliver life-saving treatments to broader markets through Lakeside's healthcare distribution capabilities.

Positive

• Strategic expansion into oncology drug distribution market
• Partnership with established pharmaceutical company listed on Shanghai Stock Exchange
• Access to drug with multiple regulatory approvals in major markets

Negative

• None.

Insights

Pharmaceutical Industry Analyst

The strategic distribution agreement between Lakeside's subsidiary Hupan Pharmaceutical and Huiyu Pharmaceutical marks a significant expansion in the oncology drug distribution landscape. Huiyu's flagship product, Pemetrexed Disodium, already has regulatory approvals in major markets including China and key European countries, indicating established market validation. The global pemetrexed market is valued at approximately $1.2 billion annually, with NSCLC treatment driving substantial demand. This partnership leverages Lakeside's established cross-border supply chain infrastructure to potentially capture a meaningful share of this market. For a company with a $20.25 million market cap, securing distribution rights for an approved oncology drug portfolio represents a transformative opportunity that could significantly impact revenue streams. The multi-country regulatory approvals reduce market entry barriers and accelerate commercialization timelines.

Supply Chain Expert

This partnership strategically positions Lakeside to capitalize on the complex cold chain requirements of oncology drugs. Specialized pharmaceutical distribution requires sophisticated temperature-controlled logistics, regulatory compliance across multiple jurisdictions and precise inventory management - areas where Lakeside's Asia-Pacific focus provides competitive advantages. The agreement's structure, utilizing Hupan Pharmaceutical as the distribution arm, indicates a well-thought-out approach to navigate China's pharmaceutical distribution regulations while maintaining quality control. For investors, this represents a potential high-margin revenue stream as specialty pharmaceutical distribution typically commands premium pricing due to the expertise and infrastructure required. The partnership also creates barriers to entry for competitors, as building similar cross-border pharmaceutical supply chain capabilities requires significant time and capital investment.

ITASCA, Ill., Jan. 7, 2025 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market today announced that Hupan Pharmaceutical has entered into a strategic distribution agreement with Sichuan Huiyu Pharmaceutical Co., Ltd. ("Huiyu Pharmaceutical").

Huiyu Pharmaceutical is a leading innovator in oncology and immune-related therapies, listed on the Shanghai Stock Exchange (688553.SS). Huiyu Pharmaceutical is renowned for its robust R&D capabilities, cutting-edge manufacturing process, and a strong commitment to address critical healthcare needs worldwide.

Under the agreement, Hupan Pharmaceutical will distribute Huiyu Pharmaceutical's highly regarded oncology and immunotherapy drugs to hospitals and healthcare institutions to domestic and global markets. Huiyu Pharmaceutical's flagship product, Pemetrexed Disodium for Injection, has received regulatory approvals in major markets, including China, the UK, Germany, and Finland, and is widely recognized for its efficacy in treating non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

Lan Su, COO of Lakeside Holding Limited, commented, "Our strategic partnership with Huiyu Pharmaceutical allows us to help expand the reach of their innovative oncology solutions and deliver life-saving treatments to broader markets. We are proud to use our healthcare distribution capabilities to reach patients domestically and abroad."

Zhao Ding, President at Huiyu Pharmaceutical, commented, "We look forward to partnering with Hupan Pharmaceutical to provide reliable and efficient distribution channels for our therapies, so they can reach patients when needed and improve patient outcomes."

About Lakeside Holding Limited

Lakeside Holding Limited is a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market. Through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd.—Lakeside delivers tailored logistics solutions spanning general and specialized sectors.

American Bear Logistics, with strategic hubs in Chicago, Dallas, Los Angeles, and New York, offers customized cross-border ocean and airfreight solutions, connecting Asia-based logistics service companies and e-commerce platforms with the U.S. market.

Lakeside recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd., expanding its service scope and enhancing its pharmaceutical logistics and distribution capabilities within China. This strategic move underscores Lakeside's commitment to advancing integrated cross-border logistics solutions.

For more information, please visit https://lakeside-holding.com.

Safe Harbor Statement

This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors, including those listed under "Risk Factors," may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements.

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

View original content:https://www.prnewswire.com/news-releases/lakeside-partners-with-huiyu-pharmaceutical-to-revolutionize-oncology-drug-distribution-302343673.html

SOURCE Lakeside Holding Limited

FAQ

What is the new distribution agreement between LSH's Hupan Pharmaceutical and Huiyu Pharmaceutical?

Hupan Pharmaceutical will distribute Huiyu Pharmaceutical's oncology and immunotherapy drugs to hospitals and healthcare institutions in domestic and global markets.

Which markets have approved Huiyu Pharmaceutical's Pemetrexed Disodium for Injection?

The drug has received regulatory approvals in China, the UK, Germany, and Finland.

What medical conditions does Huiyu's flagship product treat under LSH's distribution agreement?

Pemetrexed Disodium for Injection treats non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

How will the LSH-Huiyu partnership impact market reach?

The partnership will expand the distribution of Huiyu's oncology solutions to broader markets through Lakeside's healthcare distribution capabilities.